{{val.symbol}}
{{val.value}}

Pfizer Trading forecasts and signals

Total signals – 41

Active signals for Pfizer

Total signals – 2
Showing 1-2 of 2 items.
TraderPrecision for symbol, %Opening quoteTargetCreation dateForecast closure dateS/L and сommentPrice
Peters60.053.10
52.18
20.01.202227.01.202255.04
Millions57.1--.0-
--.0-
11.12.202031.05.20222 USD
 
 

Pfizer rate traders

Total number of traders – 9
Nina
Symbols: 34
MTS, EUR/USD, USD/RUB, Dash/USD, EthereumClassic/USD, Zcash/USD, Cardano/USD, EOS/USD, BitcoinCash/USD, Litecoin/USD, Tron/USD, NEO/USD, Ethereum/USD, Bitcoin/USD, XRP/USD, US Dollar Index, Dow Jones, S&P 500, Brent Crude Oil, Palladium, Silver, Gold, Platinum, Alphabet, Apple, AT&T, Pfizer, Facebook, Intel, Amazon, Tesla Motors, Boeing, Dogecoin, Solana
Trend
accuracy
72%
  • MTS 67%
  • EUR/USD 65%
  • USD/RUB 92%
  • Dash/USD 0%
  • EthereumClassic/USD 75%
  • Zcash/USD 25%
  • Cardano/USD 64%
  • EOS/USD 50%
  • BitcoinCash/USD 75%
  • Litecoin/USD 82%
  • Tron/USD 100%
  • NEO/USD 75%
  • Ethereum/USD 72%
  • Bitcoin/USD 73%
  • XRP/USD 74%
  • US Dollar Index 50%
  • Dow Jones 100%
  • S&P 500 56%
  • Brent Crude Oil 0%
  • Palladium 100%
  • Silver 50%
  • Gold 70%
  • Platinum 25%
  • Alphabet 100%
  • Apple 100%
  • AT&T 100%
  • Pfizer 100%
  • Facebook 50%
  • Intel 100%
  • Amazon 50%
  • Tesla Motors 100%
  • Boeing 60%
  • Dogecoin 75%
  • Solana 100%
Price
accuracy
70%
  • MTS 67%
  • EUR/USD 52%
  • USD/RUB 84%
  • Dash/USD 0%
  • EthereumClassic/USD 75%
  • Zcash/USD 25%
  • Cardano/USD 60%
  • EOS/USD 50%
  • BitcoinCash/USD 75%
  • Litecoin/USD 79%
  • Tron/USD 28%
  • NEO/USD 61%
  • Ethereum/USD 70%
  • Bitcoin/USD 72%
  • XRP/USD 74%
  • US Dollar Index 50%
  • Dow Jones 100%
  • S&P 500 52%
  • Brent Crude Oil 0%
  • Palladium 78%
  • Silver 50%
  • Gold 70%
  • Platinum 25%
  • Alphabet 38%
  • Apple 100%
  • AT&T 60%
  • Pfizer 100%
  • Facebook 50%
  • Intel 100%
  • Amazon 50%
  • Tesla Motors 83%
  • Boeing 29%
  • Dogecoin 68%
  • Solana 100%
Profitableness,
pips/day
139
  • MTS -4
  • EUR/USD 5
  • USD/RUB 2
  • Dash/USD -3
  • EthereumClassic/USD 8
  • Zcash/USD 8
  • Cardano/USD -30
  • EOS/USD -110
  • BitcoinCash/USD 97
  • Litecoin/USD 241
  • Tron/USD 28
  • NEO/USD 16
  • Ethereum/USD 45
  • Bitcoin/USD 68
  • XRP/USD 122
  • US Dollar Index -3
  • Dow Jones 61
  • S&P 500 1
  • Brent Crude Oil -9
  • Palladium 102
  • Silver -20
  • Gold 0
  • Platinum -24
  • Alphabet 37
  • Apple 37
  • AT&T 2
  • Pfizer 11
  • Facebook -1
  • Intel 200
  • Amazon 3
  • Tesla Motors 30
  • Boeing -7
  • Dogecoin -95
  • Solana 10000
More
Lime
Symbols: 47
Polymetal, Yandex, Aeroflot (MOEX), Gazprom, Nornikel, Lukoil, MTS, Sberbank (MOEX), EUR/RUB, EUR/USD, GBP/USD, USD/CAD, USD/JPY, USD/RUB, EUR/GBP, Dash/USD, Stellar/USD, EthereumClassic/USD, Zcash/USD, Cardano/USD, EOS/USD, BitcoinCash/USD, Litecoin/USD, Tron/USD, NEO/USD, Ethereum/USD, Bitcoin/USD, XRP/USD, RTS, US Dollar Index, DAX, Dow Jones, S&P 500, Brent Crude Oil, Silver, Gold, Norilsk Nickel, Alibaba, Apple, Microsoft, nVidia, Pfizer, Intel, Amazon, Tesla Motors, Binance Coin, Chainlink
Trend
accuracy
71%
  • Polymetal 50%
  • Yandex 20%
  • Aeroflot (MOEX) 25%
  • Gazprom 94%
  • Nornikel 25%
  • Lukoil 88%
  • MTS 100%
  • Sberbank (MOEX) 80%
  • EUR/RUB 100%
  • EUR/USD 90%
  • GBP/USD 100%
  • USD/CAD 50%
  • USD/JPY 0%
  • USD/RUB 62%
  • EUR/GBP 0%
  • Dash/USD 76%
  • Stellar/USD 63%
  • EthereumClassic/USD 0%
  • Zcash/USD 100%
  • Cardano/USD 75%
  • EOS/USD 75%
  • BitcoinCash/USD 67%
  • Litecoin/USD 66%
  • Tron/USD 67%
  • NEO/USD 79%
  • Ethereum/USD 61%
  • Bitcoin/USD 71%
  • XRP/USD 38%
  • RTS 100%
  • US Dollar Index 75%
  • DAX 100%
  • Dow Jones 0%
  • S&P 500 0%
  • Brent Crude Oil 67%
  • Silver 33%
  • Gold 67%
  • Norilsk Nickel 100%
  • Alibaba 60%
  • Apple 0%
  • Microsoft 100%
  • nVidia 100%
  • Pfizer 0%
  • Intel 75%
  • Amazon 60%
  • Tesla Motors 0%
  • Binance Coin 85%
  • Chainlink 80%
Price
accuracy
70%
  • Polymetal 50%
  • Yandex 20%
  • Aeroflot (MOEX) 25%
  • Gazprom 89%
  • Nornikel 25%
  • Lukoil 88%
  • MTS 64%
  • Sberbank (MOEX) 80%
  • EUR/RUB 26%
  • EUR/USD 90%
  • GBP/USD 100%
  • USD/CAD 50%
  • USD/JPY 0%
  • USD/RUB 60%
  • EUR/GBP 0%
  • Dash/USD 76%
  • Stellar/USD 63%
  • EthereumClassic/USD 0%
  • Zcash/USD 100%
  • Cardano/USD 75%
  • EOS/USD 77%
  • BitcoinCash/USD 67%
  • Litecoin/USD 63%
  • Tron/USD 67%
  • NEO/USD 77%
  • Ethereum/USD 57%
  • Bitcoin/USD 70%
  • XRP/USD 38%
  • RTS 100%
  • US Dollar Index 75%
  • DAX 100%
  • Dow Jones 0%
  • S&P 500 0%
  • Brent Crude Oil 53%
  • Silver 33%
  • Gold 53%
  • Norilsk Nickel 100%
  • Alibaba 35%
  • Apple 0%
  • Microsoft 100%
  • nVidia 100%
  • Pfizer 0%
  • Intel 75%
  • Amazon 60%
  • Tesla Motors 0%
  • Binance Coin 85%
  • Chainlink 80%
Profitableness,
pips/day
204
  • Polymetal -93
  • Yandex -28
  • Aeroflot (MOEX) -18
  • Gazprom 7
  • Nornikel -58
  • Lukoil 16
  • MTS 11
  • Sberbank (MOEX) 7
  • EUR/RUB 21
  • EUR/USD 21
  • GBP/USD 80
  • USD/CAD -22
  • USD/JPY -5
  • USD/RUB -1
  • EUR/GBP -17
  • Dash/USD 2
  • Stellar/USD -25
  • EthereumClassic/USD -3
  • Zcash/USD 800
  • Cardano/USD 111
  • EOS/USD 50
  • BitcoinCash/USD 1
  • Litecoin/USD 18
  • Tron/USD 4
  • NEO/USD 23
  • Ethereum/USD 3
  • Bitcoin/USD 84
  • XRP/USD -64
  • RTS 20
  • US Dollar Index 48
  • DAX 5
  • Dow Jones -40
  • S&P 500 -9
  • Brent Crude Oil 19
  • Silver -1
  • Gold 0
  • Norilsk Nickel 406
  • Alibaba -2
  • Apple -7
  • Microsoft 17
  • nVidia 2
  • Pfizer -3
  • Intel 12
  • Amazon -9
  • Tesla Motors -74
  • Binance Coin 535
  • Chainlink -27
More
Millions
Symbols: 52
Yandex, Sberbank (MOEX), AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, USD/RUB, EUR/AUD, EUR/NZD, GBP/AUD, AUD/NZD, EUR/JPY, GBP/JPY, AUD/JPY, NZD/USD, Dash/USD, Zcash/USD, Cardano/USD, Litecoin/USD, IOTA/USD, NEO/USD, Ethereum/USD, Monero/USD, Bitcoin/USD, XRP/USD, RTS, US Dollar Index, NASDAQ 100, S&P 500, Brent Crude Oil, WTI Crude Oil, Natural Gas, Silver, Gold, Snap, Alibaba, Apple, Lukoil, nVidia, Citigroup, Pfizer, Facebook, Twitter, Adidas, Amazon, Tesla Motors, Boeing, Binance Coin, Polkadot, Chainlink
Trend
accuracy
64%
  • Yandex 100%
  • Sberbank (MOEX) 33%
  • AUD/USD 67%
  • EUR/USD 62%
  • GBP/USD 45%
  • USD/CAD 53%
  • USD/CHF 0%
  • USD/JPY 45%
  • USD/RUB 69%
  • EUR/AUD 50%
  • EUR/NZD 33%
  • GBP/AUD 67%
  • AUD/NZD 20%
  • EUR/JPY 0%
  • GBP/JPY 75%
  • AUD/JPY 87%
  • NZD/USD 0%
  • Dash/USD 100%
  • Zcash/USD 33%
  • Cardano/USD 60%
  • Litecoin/USD 67%
  • IOTA/USD 33%
  • NEO/USD 50%
  • Ethereum/USD 66%
  • Monero/USD 50%
  • Bitcoin/USD 66%
  • XRP/USD 65%
  • RTS 58%
  • US Dollar Index 56%
  • NASDAQ 100 69%
  • S&P 500 67%
  • Brent Crude Oil 71%
  • WTI Crude Oil 60%
  • Natural Gas 65%
  • Silver 53%
  • Gold 58%
  • Snap 100%
  • Alibaba 50%
  • Apple 56%
  • Lukoil 50%
  • nVidia 33%
  • Citigroup 60%
  • Pfizer 57%
  • Facebook 45%
  • Twitter 50%
  • Adidas 50%
  • Amazon 86%
  • Tesla Motors 80%
  • Boeing 0%
  • Binance Coin 75%
  • Polkadot 100%
  • Chainlink 100%
Price
accuracy
61%
  • Yandex 100%
  • Sberbank (MOEX) 33%
  • AUD/USD 67%
  • EUR/USD 59%
  • GBP/USD 45%
  • USD/CAD 41%
  • USD/CHF 0%
  • USD/JPY 40%
  • USD/RUB 64%
  • EUR/AUD 50%
  • EUR/NZD 33%
  • GBP/AUD 67%
  • AUD/NZD 20%
  • EUR/JPY 0%
  • GBP/JPY 75%
  • AUD/JPY 87%
  • NZD/USD 0%
  • Dash/USD 7%
  • Zcash/USD 33%
  • Cardano/USD 60%
  • Litecoin/USD 67%
  • IOTA/USD 33%
  • NEO/USD 50%
  • Ethereum/USD 66%
  • Monero/USD 26%
  • Bitcoin/USD 66%
  • XRP/USD 61%
  • RTS 50%
  • US Dollar Index 51%
  • NASDAQ 100 69%
  • S&P 500 65%
  • Brent Crude Oil 63%
  • WTI Crude Oil 60%
  • Natural Gas 50%
  • Silver 53%
  • Gold 57%
  • Snap 100%
  • Alibaba 30%
  • Apple 33%
  • Lukoil 21%
  • nVidia 1%
  • Citigroup 23%
  • Pfizer 46%
  • Facebook 31%
  • Twitter 50%
  • Adidas 50%
  • Amazon 74%
  • Tesla Motors 80%
  • Boeing 0%
  • Binance Coin 75%
  • Polkadot 92%
  • Chainlink 100%
Profitableness,
pips/day
117
  • Yandex 107
  • Sberbank (MOEX) -21
  • AUD/USD 7
  • EUR/USD -4
  • GBP/USD -19
  • USD/CAD 5
  • USD/CHF -9
  • USD/JPY -1
  • USD/RUB 2
  • EUR/AUD 14
  • EUR/NZD -26
  • GBP/AUD 8
  • AUD/NZD -12
  • EUR/JPY -30
  • GBP/JPY 33
  • AUD/JPY 24
  • NZD/USD -33
  • Dash/USD 1
  • Zcash/USD -45
  • Cardano/USD -161
  • Litecoin/USD 593
  • IOTA/USD -353
  • NEO/USD 0
  • Ethereum/USD 42
  • Monero/USD -50
  • Bitcoin/USD 96
  • XRP/USD 86
  • RTS -2
  • US Dollar Index 0
  • NASDAQ 100 3
  • S&P 500 6
  • Brent Crude Oil 21
  • WTI Crude Oil -2
  • Natural Gas 2
  • Silver -2
  • Gold 0
  • Snap 150
  • Alibaba 11
  • Apple 1
  • Lukoil -6
  • nVidia -1
  • Citigroup 4
  • Pfizer -1
  • Facebook -4
  • Twitter -101
  • Adidas -12
  • Amazon 3
  • Tesla Motors 16
  • Boeing -46
  • Binance Coin 202
  • Polkadot 842
  • Chainlink 100
More
TorForex
Symbols: 77
Yandex, Gazprom, Nornikel, Lukoil, Novatek, Polyus, Rosneft, Sberbank (MOEX), AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, USD/RUB, NZD/USD, Stellar/USD, Cardano/USD, BitcoinCash/USD, Litecoin/USD, Tron/USD, Ethereum/USD, Monero/USD, Bitcoin/USD, XRP/USD, Brent Crude Oil, Gold, Snap, Alphabet, Alibaba, Visa, Hewlett-Packard, Home Depot, Adobe Systems, MasterCard, Starbucks, Nike, Uber Technologies, Apple, American Express, JPMorgan Chase, Microsoft, Netflix, IBM, Procter & Gamble, Pinterest, Coca-Cola, nVidia, Baidu, Pfizer, Cisco Systems, Facebook, Twitter, SAP, Caterpillar, Toyota Motor, Bank of America, Goldman Sachs Group, Salesforce, eBay, General Electrics, Intel, Ford Motor, Walt Disney, Exxon Mobil, PetroChina, UnitedHealth Group, Amazon, Oracle, Tesla Motors, Boeing, Dogecoin, Binance Coin, Polkadot, PepsiCo, Solana, Terra
Trend
accuracy
70%
  • Yandex 78%
  • Gazprom 82%
  • Nornikel 0%
  • Lukoil 84%
  • Novatek 25%
  • Polyus 100%
  • Rosneft 75%
  • Sberbank (MOEX) 70%
  • AUD/USD 71%
  • EUR/USD 67%
  • GBP/USD 67%
  • USD/CAD 69%
  • USD/CHF 62%
  • USD/JPY 70%
  • USD/RUB 70%
  • NZD/USD 69%
  • Stellar/USD 75%
  • Cardano/USD 68%
  • BitcoinCash/USD 77%
  • Litecoin/USD 75%
  • Tron/USD 67%
  • Ethereum/USD 74%
  • Monero/USD 100%
  • Bitcoin/USD 75%
  • XRP/USD 68%
  • Brent Crude Oil 70%
  • Gold 68%
  • Snap 50%
  • Alphabet 83%
  • Alibaba 33%
  • Visa 40%
  • Hewlett-Packard 75%
  • Home Depot 75%
  • Adobe Systems 88%
  • MasterCard 75%
  • Starbucks 0%
  • Nike 75%
  • Uber Technologies 50%
  • Apple 83%
  • American Express 75%
  • JPMorgan Chase 33%
  • Microsoft 88%
  • Netflix 80%
  • IBM 50%
  • Procter & Gamble 0%
  • Pinterest 33%
  • Coca-Cola 100%
  • nVidia 60%
  • Baidu 50%
  • Pfizer 100%
  • Cisco Systems 50%
  • Facebook 100%
  • Twitter 67%
  • SAP 50%
  • Caterpillar 0%
  • Toyota Motor 25%
  • Bank of America 100%
  • Goldman Sachs Group 33%
  • Salesforce 50%
  • eBay 25%
  • General Electrics 0%
  • Intel 50%
  • Ford Motor 100%
  • Walt Disney 0%
  • Exxon Mobil 75%
  • PetroChina 0%
  • UnitedHealth Group 75%
  • Amazon 71%
  • Oracle 86%
  • Tesla Motors 80%
  • Boeing 33%
  • Dogecoin 66%
  • Binance Coin 75%
  • Polkadot 75%
  • PepsiCo 67%
  • Solana 86%
  • Terra 75%
Price
accuracy
69%
  • Yandex 78%
  • Gazprom 83%
  • Nornikel 0%
  • Lukoil 84%
  • Novatek 25%
  • Polyus 82%
  • Rosneft 75%
  • Sberbank (MOEX) 73%
  • AUD/USD 71%
  • EUR/USD 65%
  • GBP/USD 67%
  • USD/CAD 68%
  • USD/CHF 60%
  • USD/JPY 69%
  • USD/RUB 69%
  • NZD/USD 69%
  • Stellar/USD 75%
  • Cardano/USD 68%
  • BitcoinCash/USD 77%
  • Litecoin/USD 73%
  • Tron/USD 67%
  • Ethereum/USD 74%
  • Monero/USD 100%
  • Bitcoin/USD 75%
  • XRP/USD 68%
  • Brent Crude Oil 70%
  • Gold 68%
  • Snap 50%
  • Alphabet 83%
  • Alibaba 33%
  • Visa 40%
  • Hewlett-Packard 75%
  • Home Depot 75%
  • Adobe Systems 88%
  • MasterCard 75%
  • Starbucks 0%
  • Nike 67%
  • Uber Technologies 84%
  • Apple 67%
  • American Express 75%
  • JPMorgan Chase 33%
  • Microsoft 82%
  • Netflix 80%
  • IBM 50%
  • Procter & Gamble 0%
  • Pinterest 33%
  • Coca-Cola 51%
  • nVidia 60%
  • Baidu 50%
  • Pfizer 100%
  • Cisco Systems 29%
  • Facebook 100%
  • Twitter 67%
  • SAP 50%
  • Caterpillar 0%
  • Toyota Motor 25%
  • Bank of America 87%
  • Goldman Sachs Group 33%
  • Salesforce 50%
  • eBay 25%
  • General Electrics 0%
  • Intel 50%
  • Ford Motor 84%
  • Walt Disney 0%
  • Exxon Mobil 75%
  • PetroChina 0%
  • UnitedHealth Group 75%
  • Amazon 71%
  • Oracle 86%
  • Tesla Motors 72%
  • Boeing 33%
  • Dogecoin 66%
  • Binance Coin 75%
  • Polkadot 75%
  • PepsiCo 48%
  • Solana 86%
  • Terra 75%
Profitableness,
pips/day
2
  • Yandex -347
  • Gazprom 3
  • Nornikel -26
  • Lukoil 2
  • Novatek -74
  • Polyus 14
  • Rosneft 3
  • Sberbank (MOEX) -5
  • AUD/USD 3
  • EUR/USD 1
  • GBP/USD -2
  • USD/CAD 1
  • USD/CHF -3
  • USD/JPY 2
  • USD/RUB 0
  • NZD/USD 3
  • Stellar/USD -88
  • Cardano/USD -111
  • BitcoinCash/USD 7
  • Litecoin/USD 57
  • Tron/USD -20
  • Ethereum/USD 96
  • Monero/USD 80
  • Bitcoin/USD 110
  • XRP/USD 35
  • Brent Crude Oil -2
  • Gold 0
  • Snap -70
  • Alphabet 8
  • Alibaba -7
  • Visa -7
  • Hewlett-Packard 9
  • Home Depot 6
  • Adobe Systems 3
  • MasterCard 36
  • Starbucks -42
  • Nike 13
  • Uber Technologies 12
  • Apple 0
  • American Express 2
  • JPMorgan Chase -20
  • Microsoft 3
  • Netflix 2
  • IBM -49
  • Procter & Gamble -31
  • Pinterest -44
  • Coca-Cola 11
  • nVidia 0
  • Baidu -36
  • Pfizer 8
  • Cisco Systems -3
  • Facebook 45
  • Twitter -33
  • SAP -15
  • Caterpillar -46
  • Toyota Motor -34
  • Bank of America 8
  • Goldman Sachs Group -68
  • Salesforce 20
  • eBay -21
  • General Electrics -32
  • Intel 3
  • Ford Motor 8
  • Walt Disney -95
  • Exxon Mobil 6
  • PetroChina -25
  • UnitedHealth Group -25
  • Amazon -4
  • Oracle 17
  • Tesla Motors 3
  • Boeing -5
  • Dogecoin -203
  • Binance Coin -5
  • Polkadot -11
  • PepsiCo -1
  • Solana 2200
  • Terra 300
More
Cox
Symbols: 89
AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, USD/ZAR, CAD/CHF, EUR/AUD, EUR/NZD, EUR/GBP, USD/CNH, CAD/JPY, USD/SGD, EUR/CHF, GBP/AUD, GBP/NZD, AUD/NZD, GBP/CHF, EUR/SGD, NZD/CHF, AUD/CHF, EUR/JPY, EUR/SEK, CHF/JPY, EUR/CAD, GBP/JPY, NZD/JPY, AUD/JPY, NZD/USD, GBP/CAD, NZD/CAD, AUD/CAD, Dash/USD, Cardano/USD, EOS/USD, BitcoinCash/USD, Litecoin/Bitcoin, Litecoin/USD, IOTA/USD, Tron/USD, NEO/USD, Ethereum/USD, Bitcoin/USD, XRP/USD, US Dollar Index, NASDAQ 100, S&P 500, RUSSELL 2000, FTSE 100, WTI Crude Oil, Natural Gas, Silver, Gold, Copper, Alphabet, Alibaba, Hewlett-Packard, Home Depot, Apple, AT&T, Verizon, JPMorgan Chase, Johnson&Johnson, Microsoft, McDonald's, IBM, Procter & Gamble, Coca-Cola, Citigroup, Pfizer, Cisco Systems, Facebook, Twitter, Goldman Sachs Group, eBay, General Electrics, Intel, Walt Disney, Exxon Mobil, Amazon, Tesla Motors, Boeing, Coffee, Dogecoin, Binance Coin, Chainlink, Solana, EUR/ZAR
Trend
accuracy
68%
  • AUD/USD 57%
  • EUR/USD 64%
  • GBP/USD 71%
  • USD/CAD 67%
  • USD/CHF 56%
  • USD/JPY 66%
  • USD/ZAR 79%
  • CAD/CHF 33%
  • EUR/AUD 71%
  • EUR/NZD 67%
  • EUR/GBP 59%
  • USD/CNH 75%
  • CAD/JPY 84%
  • USD/SGD 71%
  • EUR/CHF 57%
  • GBP/AUD 66%
  • GBP/NZD 61%
  • AUD/NZD 53%
  • GBP/CHF 73%
  • EUR/SGD 83%
  • NZD/CHF 36%
  • AUD/CHF 14%
  • EUR/JPY 74%
  • EUR/SEK 100%
  • CHF/JPY 75%
  • EUR/CAD 64%
  • GBP/JPY 71%
  • NZD/JPY 57%
  • AUD/JPY 63%
  • NZD/USD 63%
  • GBP/CAD 50%
  • NZD/CAD 45%
  • AUD/CAD 82%
  • Dash/USD 57%
  • Cardano/USD 86%
  • EOS/USD 60%
  • BitcoinCash/USD 80%
  • Litecoin/Bitcoin 67%
  • Litecoin/USD 92%
  • IOTA/USD 33%
  • Tron/USD 64%
  • NEO/USD 100%
  • Ethereum/USD 69%
  • Bitcoin/USD 71%
  • XRP/USD 90%
  • US Dollar Index 100%
  • NASDAQ 100 86%
  • S&P 500 79%
  • RUSSELL 2000 50%
  • FTSE 100 100%
  • WTI Crude Oil 76%
  • Natural Gas 83%
  • Silver 71%
  • Gold 67%
  • Copper 40%
  • Alphabet 95%
  • Alibaba 90%
  • Hewlett-Packard 75%
  • Home Depot 75%
  • Apple 74%
  • AT&T 100%
  • Verizon 0%
  • JPMorgan Chase 100%
  • Johnson&Johnson 83%
  • Microsoft 60%
  • McDonald's 67%
  • IBM 100%
  • Procter & Gamble 100%
  • Coca-Cola 100%
  • Citigroup 75%
  • Pfizer 79%
  • Cisco Systems 50%
  • Facebook 86%
  • Twitter 60%
  • Goldman Sachs Group 50%
  • eBay 0%
  • General Electrics 63%
  • Intel 67%
  • Walt Disney 50%
  • Exxon Mobil 100%
  • Amazon 88%
  • Tesla Motors 79%
  • Boeing 50%
  • Coffee 60%
  • Dogecoin 50%
  • Binance Coin 50%
  • Chainlink 75%
  • Solana 25%
  • EUR/ZAR 50%
Price
accuracy
67%
  • AUD/USD 57%
  • EUR/USD 63%
  • GBP/USD 70%
  • USD/CAD 67%
  • USD/CHF 58%
  • USD/JPY 64%
  • USD/ZAR 79%
  • CAD/CHF 32%
  • EUR/AUD 70%
  • EUR/NZD 67%
  • EUR/GBP 50%
  • USD/CNH 75%
  • CAD/JPY 78%
  • USD/SGD 71%
  • EUR/CHF 53%
  • GBP/AUD 66%
  • GBP/NZD 61%
  • AUD/NZD 50%
  • GBP/CHF 71%
  • EUR/SGD 83%
  • NZD/CHF 36%
  • AUD/CHF 14%
  • EUR/JPY 72%
  • EUR/SEK 78%
  • CHF/JPY 75%
  • EUR/CAD 62%
  • GBP/JPY 71%
  • NZD/JPY 57%
  • AUD/JPY 63%
  • NZD/USD 61%
  • GBP/CAD 50%
  • NZD/CAD 41%
  • AUD/CAD 75%
  • Dash/USD 57%
  • Cardano/USD 81%
  • EOS/USD 60%
  • BitcoinCash/USD 80%
  • Litecoin/Bitcoin 67%
  • Litecoin/USD 92%
  • IOTA/USD 33%
  • Tron/USD 60%
  • NEO/USD 100%
  • Ethereum/USD 69%
  • Bitcoin/USD 71%
  • XRP/USD 89%
  • US Dollar Index 100%
  • NASDAQ 100 86%
  • S&P 500 67%
  • RUSSELL 2000 50%
  • FTSE 100 100%
  • WTI Crude Oil 76%
  • Natural Gas 83%
  • Silver 71%
  • Gold 66%
  • Copper 40%
  • Alphabet 95%
  • Alibaba 90%
  • Hewlett-Packard 75%
  • Home Depot 75%
  • Apple 74%
  • AT&T 100%
  • Verizon 0%
  • JPMorgan Chase 100%
  • Johnson&Johnson 83%
  • Microsoft 52%
  • McDonald's 67%
  • IBM 100%
  • Procter & Gamble 100%
  • Coca-Cola 100%
  • Citigroup 75%
  • Pfizer 79%
  • Cisco Systems 50%
  • Facebook 74%
  • Twitter 43%
  • Goldman Sachs Group 19%
  • eBay 0%
  • General Electrics 63%
  • Intel 64%
  • Walt Disney 43%
  • Exxon Mobil 52%
  • Amazon 88%
  • Tesla Motors 74%
  • Boeing 11%
  • Coffee 60%
  • Dogecoin 50%
  • Binance Coin 50%
  • Chainlink 75%
  • Solana 25%
  • EUR/ZAR 50%
Profitableness,
pips/day
-35
  • AUD/USD -7
  • EUR/USD -4
  • GBP/USD 3
  • USD/CAD 0
  • USD/CHF -1
  • USD/JPY 0
  • USD/ZAR 3
  • CAD/CHF -9
  • EUR/AUD 2
  • EUR/NZD -5
  • EUR/GBP 2
  • USD/CNH 0
  • CAD/JPY 8
  • USD/SGD 6
  • EUR/CHF -2
  • GBP/AUD -3
  • GBP/NZD -7
  • AUD/NZD -4
  • GBP/CHF 0
  • EUR/SGD 13
  • NZD/CHF -13
  • AUD/CHF -16
  • EUR/JPY 4
  • EUR/SEK 77
  • CHF/JPY 11
  • EUR/CAD 4
  • GBP/JPY 2
  • NZD/JPY -7
  • AUD/JPY -7
  • NZD/USD -2
  • GBP/CAD -14
  • NZD/CAD -9
  • AUD/CAD 6
  • Dash/USD -175
  • Cardano/USD 269
  • EOS/USD -52
  • BitcoinCash/USD 29
  • Litecoin/Bitcoin 0
  • Litecoin/USD 618
  • IOTA/USD -200
  • Tron/USD 29
  • NEO/USD 125
  • Ethereum/USD 72
  • Bitcoin/USD -44
  • XRP/USD 398
  • US Dollar Index 27
  • NASDAQ 100 34
  • S&P 500 2
  • RUSSELL 2000 -67
  • FTSE 100 20
  • WTI Crude Oil 37
  • Natural Gas -28
  • Silver 2
  • Gold 0
  • Copper -317
  • Alphabet 32
  • Alibaba 4
  • Hewlett-Packard 7
  • Home Depot 0
  • Apple 3
  • AT&T 16
  • Verizon -8
  • JPMorgan Chase 100
  • Johnson&Johnson 16
  • Microsoft -4
  • McDonald's 1
  • IBM 43
  • Procter & Gamble 600
  • Coca-Cola 27
  • Citigroup 3
  • Pfizer -6
  • Cisco Systems 6
  • Facebook 12
  • Twitter -8
  • Goldman Sachs Group -90
  • eBay -46
  • General Electrics -10
  • Intel 4
  • Walt Disney 13
  • Exxon Mobil 10
  • Amazon -1
  • Tesla Motors -33
  • Boeing -2
  • Coffee -33
  • Dogecoin -487
  • Binance Coin -1000
  • Chainlink -5
  • Solana -17000
  • EUR/ZAR -350
More
Erlan
Symbols: 70
AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, CAD/CHF, EUR/AUD, EUR/NZD, EUR/GBP, CAD/JPY, EUR/CHF, GBP/AUD, GBP/NZD, AUD/NZD, GBP/CHF, NZD/CHF, AUD/CHF, EUR/JPY, CHF/JPY, EUR/CAD, GBP/JPY, NZD/JPY, AUD/JPY, NZD/USD, GBP/CAD, NZD/CAD, AUD/CAD, Stellar/USD, EthereumClassic/USD, Cardano/USD, EOS/USD, BitcoinCash/USD, Litecoin/USD, Ethereum/USD, Bitcoin/USD, XRP/USD, US Dollar Index, Dow Jones, NASDAQ 100, S&P 500, RUSSELL 2000, Brent Crude Oil, WTI Crude Oil, Natural Gas, Silver, Gold, Copper, Alibaba, Uber Technologies, Apple, Coca-Cola, nVidia, Citigroup, Pfizer, Facebook, eBay, General Electrics, Ford Motor, Amazon, LYFT, Tesla Motors, Aurora Cannabis, Boeing, Dogecoin, Binance Coin, Uniswap, Chainlink, BitTorrent, VeChain
Trend
accuracy
67%
  • AUD/USD 61%
  • EUR/USD 63%
  • GBP/USD 68%
  • USD/CAD 62%
  • USD/CHF 78%
  • USD/JPY 60%
  • CAD/CHF 53%
  • EUR/AUD 73%
  • EUR/NZD 71%
  • EUR/GBP 80%
  • CAD/JPY 80%
  • EUR/CHF 53%
  • GBP/AUD 63%
  • GBP/NZD 79%
  • AUD/NZD 61%
  • GBP/CHF 66%
  • NZD/CHF 63%
  • AUD/CHF 31%
  • EUR/JPY 68%
  • CHF/JPY 76%
  • EUR/CAD 70%
  • GBP/JPY 64%
  • NZD/JPY 33%
  • AUD/JPY 44%
  • NZD/USD 55%
  • GBP/CAD 33%
  • NZD/CAD 71%
  • AUD/CAD 52%
  • Stellar/USD 89%
  • EthereumClassic/USD 100%
  • Cardano/USD 68%
  • EOS/USD 71%
  • BitcoinCash/USD 75%
  • Litecoin/USD 60%
  • Ethereum/USD 80%
  • Bitcoin/USD 77%
  • XRP/USD 65%
  • US Dollar Index 0%
  • Dow Jones 100%
  • NASDAQ 100 44%
  • S&P 500 70%
  • RUSSELL 2000 71%
  • Brent Crude Oil 100%
  • WTI Crude Oil 73%
  • Natural Gas 78%
  • Silver 78%
  • Gold 65%
  • Copper 67%
  • Alibaba 80%
  • Uber Technologies 0%
  • Apple 100%
  • Coca-Cola 0%
  • nVidia 0%
  • Citigroup 50%
  • Pfizer 0%
  • Facebook 50%
  • eBay 33%
  • General Electrics 100%
  • Ford Motor 33%
  • Amazon 0%
  • LYFT 100%
  • Tesla Motors 62%
  • Aurora Cannabis 25%
  • Boeing 75%
  • Dogecoin 0%
  • Binance Coin 67%
  • Uniswap 80%
  • Chainlink 92%
  • BitTorrent 80%
  • VeChain 50%
Price
accuracy
66%
  • AUD/USD 61%
  • EUR/USD 60%
  • GBP/USD 67%
  • USD/CAD 62%
  • USD/CHF 78%
  • USD/JPY 60%
  • CAD/CHF 49%
  • EUR/AUD 73%
  • EUR/NZD 71%
  • EUR/GBP 76%
  • CAD/JPY 80%
  • EUR/CHF 50%
  • GBP/AUD 63%
  • GBP/NZD 79%
  • AUD/NZD 61%
  • GBP/CHF 66%
  • NZD/CHF 63%
  • AUD/CHF 26%
  • EUR/JPY 63%
  • CHF/JPY 77%
  • EUR/CAD 68%
  • GBP/JPY 64%
  • NZD/JPY 33%
  • AUD/JPY 44%
  • NZD/USD 55%
  • GBP/CAD 26%
  • NZD/CAD 64%
  • AUD/CAD 40%
  • Stellar/USD 89%
  • EthereumClassic/USD 100%
  • Cardano/USD 68%
  • EOS/USD 71%
  • BitcoinCash/USD 75%
  • Litecoin/USD 60%
  • Ethereum/USD 80%
  • Bitcoin/USD 77%
  • XRP/USD 65%
  • US Dollar Index 0%
  • Dow Jones 100%
  • NASDAQ 100 42%
  • S&P 500 61%
  • RUSSELL 2000 71%
  • Brent Crude Oil 100%
  • WTI Crude Oil 73%
  • Natural Gas 78%
  • Silver 78%
  • Gold 65%
  • Copper 67%
  • Alibaba 66%
  • Uber Technologies 0%
  • Apple 89%
  • Coca-Cola 0%
  • nVidia 0%
  • Citigroup 50%
  • Pfizer 0%
  • Facebook 50%
  • eBay 33%
  • General Electrics 14%
  • Ford Motor 33%
  • Amazon 0%
  • LYFT 100%
  • Tesla Motors 62%
  • Aurora Cannabis 25%
  • Boeing 37%
  • Dogecoin 0%
  • Binance Coin 67%
  • Uniswap 80%
  • Chainlink 92%
  • BitTorrent 60%
  • VeChain 50%
Profitableness,
pips/day
4
  • AUD/USD -2
  • EUR/USD 0
  • GBP/USD -2
  • USD/CAD -8
  • USD/CHF 11
  • USD/JPY 4
  • CAD/CHF -7
  • EUR/AUD 4
  • EUR/NZD 5
  • EUR/GBP 5
  • CAD/JPY 10
  • EUR/CHF -1
  • GBP/AUD -4
  • GBP/NZD 14
  • AUD/NZD -10
  • GBP/CHF -3
  • NZD/CHF 2
  • AUD/CHF -10
  • EUR/JPY -1
  • CHF/JPY 6
  • EUR/CAD 4
  • GBP/JPY -9
  • NZD/JPY -10
  • AUD/JPY -16
  • NZD/USD -4
  • GBP/CAD -19
  • NZD/CAD 0
  • AUD/CAD -8
  • Stellar/USD 29
  • EthereumClassic/USD 200
  • Cardano/USD -272
  • EOS/USD 16
  • BitcoinCash/USD 50
  • Litecoin/USD 160
  • Ethereum/USD 201
  • Bitcoin/USD 38
  • XRP/USD 27
  • US Dollar Index -6
  • Dow Jones 95
  • NASDAQ 100 -42
  • S&P 500 -3
  • RUSSELL 2000 -42
  • Brent Crude Oil 80
  • WTI Crude Oil 4
  • Natural Gas -25
  • Silver 7
  • Gold -2
  • Copper 50
  • Alibaba 3
  • Uber Technologies -23
  • Apple 6
  • Coca-Cola 0
  • nVidia 0
  • Citigroup -30
  • Pfizer -111
  • Facebook 0
  • eBay -1
  • General Electrics 1
  • Ford Motor -2
  • Amazon -6
  • LYFT 506
  • Tesla Motors -9
  • Aurora Cannabis -13
  • Boeing -1
  • Dogecoin -400
  • Binance Coin -450
  • Uniswap 500
  • Chainlink 48
  • BitTorrent 65
  • VeChain -18
More
TORRO
Symbols: 51
AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/TRY, EUR/NZD, EUR/GBP, USD/CNH, CAD/JPY, USD/SGD, EUR/CHF, GBP/AUD, GBP/NZD, USD/SEK, AUD/NZD, EUR/SGD, NZD/CHF, AUD/CHF, EUR/JPY, EUR/CAD, GBP/JPY, NZD/JPY, AUD/JPY, NZD/CAD, AUD/CAD, Dash/Bitcoin, Stellar/USD, Litecoin/Bitcoin, Litecoin/USD, Bitcoin/USD, XRP/USD, US Dollar Index, Dow Jones, NASDAQ 100, S&P 500, Brent Crude Oil, WTI Crude Oil, Silver, Gold, Platinum, Visa, Activision Blizzard, Uber Technologies, Apple, Microsoft, Pfizer, Facebook, Twitter, Amazon, Tesla Motors
Trend
accuracy
66%
  • AUD/USD 25%
  • EUR/USD 91%
  • GBP/USD 67%
  • USD/CAD 0%
  • USD/CHF 60%
  • USD/TRY 73%
  • EUR/NZD 100%
  • EUR/GBP 50%
  • USD/CNH 71%
  • CAD/JPY 80%
  • USD/SGD 50%
  • EUR/CHF 50%
  • GBP/AUD 75%
  • GBP/NZD 78%
  • USD/SEK 0%
  • AUD/NZD 75%
  • EUR/SGD 50%
  • NZD/CHF 50%
  • AUD/CHF 0%
  • EUR/JPY 75%
  • EUR/CAD 67%
  • GBP/JPY 67%
  • NZD/JPY 33%
  • AUD/JPY 100%
  • NZD/CAD 100%
  • AUD/CAD 100%
  • Dash/Bitcoin 0%
  • Stellar/USD 50%
  • Litecoin/Bitcoin 100%
  • Litecoin/USD 100%
  • Bitcoin/USD 85%
  • XRP/USD 50%
  • US Dollar Index 33%
  • Dow Jones 75%
  • NASDAQ 100 50%
  • S&P 500 70%
  • Brent Crude Oil 75%
  • WTI Crude Oil 71%
  • Silver 50%
  • Gold 58%
  • Platinum 100%
  • Visa 50%
  • Activision Blizzard 50%
  • Uber Technologies 67%
  • Apple 100%
  • Microsoft 50%
  • Pfizer 0%
  • Facebook 50%
  • Twitter 33%
  • Amazon 67%
  • Tesla Motors 100%
Price
accuracy
59%
  • AUD/USD 25%
  • EUR/USD 89%
  • GBP/USD 67%
  • USD/CAD 12%
  • USD/CHF 60%
  • USD/TRY 62%
  • EUR/NZD 100%
  • EUR/GBP 25%
  • USD/CNH 71%
  • CAD/JPY 80%
  • USD/SGD 8%
  • EUR/CHF 50%
  • GBP/AUD 75%
  • GBP/NZD 78%
  • USD/SEK 0%
  • AUD/NZD 75%
  • EUR/SGD 50%
  • NZD/CHF 29%
  • AUD/CHF 0%
  • EUR/JPY 63%
  • EUR/CAD 35%
  • GBP/JPY 50%
  • NZD/JPY 33%
  • AUD/JPY 32%
  • NZD/CAD 100%
  • AUD/CAD 100%
  • Dash/Bitcoin 0%
  • Stellar/USD 40%
  • Litecoin/Bitcoin 22%
  • Litecoin/USD 100%
  • Bitcoin/USD 65%
  • XRP/USD 50%
  • US Dollar Index 33%
  • Dow Jones 61%
  • NASDAQ 100 50%
  • S&P 500 57%
  • Brent Crude Oil 75%
  • WTI Crude Oil 71%
  • Silver 42%
  • Gold 53%
  • Platinum 100%
  • Visa 22%
  • Activision Blizzard 50%
  • Uber Technologies 67%
  • Apple 90%
  • Microsoft 8%
  • Pfizer 0%
  • Facebook 50%
  • Twitter 33%
  • Amazon 67%
  • Tesla Motors 100%
Profitableness,
pips/day
7
  • AUD/USD -14
  • EUR/USD 22
  • GBP/USD 14
  • USD/CAD -6
  • USD/CHF -11
  • USD/TRY 47
  • EUR/NZD 20
  • EUR/GBP -9
  • USD/CNH 33
  • CAD/JPY 4
  • USD/SGD -2
  • EUR/CHF 6
  • GBP/AUD -15
  • GBP/NZD 6
  • USD/SEK -502
  • AUD/NZD 9
  • EUR/SGD 10
  • NZD/CHF 2
  • AUD/CHF -11
  • EUR/JPY 5
  • EUR/CAD 0
  • GBP/JPY 6
  • NZD/JPY -4
  • AUD/JPY 11
  • NZD/CAD 10
  • AUD/CAD 33
  • Dash/Bitcoin 0
  • Stellar/USD 4
  • Litecoin/Bitcoin 0
  • Litecoin/USD 112
  • Bitcoin/USD 37
  • XRP/USD -12
  • US Dollar Index -6
  • Dow Jones 17
  • NASDAQ 100 -100
  • S&P 500 4
  • Brent Crude Oil 76
  • WTI Crude Oil 11
  • Silver -10
  • Gold -2
  • Platinum 100
  • Visa -3
  • Activision Blizzard -58
  • Uber Technologies 2
  • Apple 8
  • Microsoft -7
  • Pfizer -3
  • Facebook -13
  • Twitter -29
  • Amazon -23
  • Tesla Motors 100
More
8-Len
Symbols: 32
AUD/USD, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, CAD/CHF, EUR/AUD, EUR/NZD, EUR/GBP, CAD/JPY, EUR/CHF, GBP/AUD, AUD/NZD, GBP/CHF, NZD/CHF, EUR/JPY, CHF/JPY, EUR/CAD, GBP/JPY, NZD/JPY, AUD/JPY, NZD/USD, GBP/CAD, NZD/CAD, AUD/CAD, Litecoin/USD, Bitcoin/USD, S&P 500, Gold, Pfizer, Adidas
Trend
accuracy
61%
  • AUD/USD 25%
  • EUR/USD 58%
  • GBP/USD 63%
  • USD/CAD 57%
  • USD/CHF 67%
  • USD/JPY 57%
  • CAD/CHF 50%
  • EUR/AUD 64%
  • EUR/NZD 56%
  • EUR/GBP 67%
  • CAD/JPY 50%
  • EUR/CHF 0%
  • GBP/AUD 65%
  • AUD/NZD 50%
  • GBP/CHF 60%
  • NZD/CHF 75%
  • EUR/JPY 50%
  • CHF/JPY 75%
  • EUR/CAD 63%
  • GBP/JPY 50%
  • NZD/JPY 0%
  • AUD/JPY 63%
  • NZD/USD 67%
  • GBP/CAD 100%
  • NZD/CAD 20%
  • AUD/CAD 0%
  • Litecoin/USD 100%
  • Bitcoin/USD 71%
  • S&P 500 100%
  • Gold 83%
  • Pfizer 100%
  • Adidas 33%
Price
accuracy
51%
  • AUD/USD 25%
  • EUR/USD 41%
  • GBP/USD 52%
  • USD/CAD 49%
  • USD/CHF 42%
  • USD/JPY 57%
  • CAD/CHF 50%
  • EUR/AUD 59%
  • EUR/NZD 45%
  • EUR/GBP 47%
  • CAD/JPY 40%
  • EUR/CHF 0%
  • GBP/AUD 56%
  • AUD/NZD 50%
  • GBP/CHF 38%
  • NZD/CHF 53%
  • EUR/JPY 45%
  • CHF/JPY 31%
  • EUR/CAD 44%
  • GBP/JPY 46%
  • NZD/JPY 0%
  • AUD/JPY 54%
  • NZD/USD 56%
  • GBP/CAD 100%
  • NZD/CAD 12%
  • AUD/CAD 0%
  • Litecoin/USD 3%
  • Bitcoin/USD 63%
  • S&P 500 100%
  • Gold 80%
  • Pfizer 49%
  • Adidas 33%
Profitableness,
pips/day
10
  • AUD/USD -9
  • EUR/USD 3
  • GBP/USD -3
  • USD/CAD -2
  • USD/CHF 1
  • USD/JPY -6
  • CAD/CHF 9
  • EUR/AUD -6
  • EUR/NZD 26
  • EUR/GBP 3
  • CAD/JPY -13
  • EUR/CHF -9
  • GBP/AUD 3
  • AUD/NZD 1
  • GBP/CHF 13
  • NZD/CHF 3
  • EUR/JPY 1
  • CHF/JPY 1
  • EUR/CAD 7
  • GBP/JPY 12
  • NZD/JPY -12
  • AUD/JPY 12
  • NZD/USD -2
  • GBP/CAD 75
  • NZD/CAD 0
  • AUD/CAD -51
  • Litecoin/USD 9
  • Bitcoin/USD 48
  • S&P 500 40
  • Gold 2
  • Pfizer 6
  • Adidas -43
More
Peters
Symbols: 65
AFK Sistema, AUD/USD, EUR/RUB, EUR/USD, GBP/USD, USD/CAD, USD/CHF, USD/JPY, USD/RUB, CAD/CHF, EUR/AUD, EUR/NZD, EUR/GBP, USD/DKK, CAD/JPY, USD/NOK, EUR/CHF, GBP/AUD, GBP/NZD, USD/SEK, AUD/NZD, GBP/CHF, NZD/CHF, AUD/CHF, EUR/JPY, CHF/JPY, EUR/CAD, GBP/JPY, NZD/JPY, AUD/JPY, NZD/USD, GBP/CAD, NZD/CAD, AUD/CAD, Dash/Bitcoin, BitcoinCash/USD, Litecoin/USD, Ethereum/USD, Bitcoin/USD, XRP/USD, Silver, Gold, Alphabet, Hewlett-Packard, Adobe Systems, Starbucks, Nike, Apple, American Express, JPMorgan Chase, Microsoft, McDonald's, Netflix, IBM, Procter & Gamble, Coca-Cola, Pfizer, Twitter, Bank of America, Goldman Sachs Group, General Electrics, Amazon, Oracle, Tesla Motors, PepsiCo
Trend
accuracy
57%
  • AFK Sistema 50%
  • AUD/USD 58%
  • EUR/RUB 80%
  • EUR/USD 51%
  • GBP/USD 57%
  • USD/CAD 52%
  • USD/CHF 49%
  • USD/JPY 50%
  • USD/RUB 0%
  • CAD/CHF 50%
  • EUR/AUD 51%
  • EUR/NZD 65%
  • EUR/GBP 57%
  • USD/DKK 62%
  • CAD/JPY 46%
  • USD/NOK 38%
  • EUR/CHF 52%
  • GBP/AUD 59%
  • GBP/NZD 76%
  • USD/SEK 51%
  • AUD/NZD 58%
  • GBP/CHF 55%
  • NZD/CHF 45%
  • AUD/CHF 52%
  • EUR/JPY 55%
  • CHF/JPY 54%
  • EUR/CAD 57%
  • GBP/JPY 62%
  • NZD/JPY 54%
  • AUD/JPY 52%
  • NZD/USD 49%
  • GBP/CAD 55%
  • NZD/CAD 55%
  • AUD/CAD 55%
  • Dash/Bitcoin 0%
  • BitcoinCash/USD 65%
  • Litecoin/USD 61%
  • Ethereum/USD 61%
  • Bitcoin/USD 69%
  • XRP/USD 60%
  • Silver 56%
  • Gold 58%
  • Alphabet 75%
  • Hewlett-Packard 0%
  • Adobe Systems 50%
  • Starbucks 67%
  • Nike 79%
  • Apple 41%
  • American Express 70%
  • JPMorgan Chase 43%
  • Microsoft 55%
  • McDonald's 50%
  • Netflix 36%
  • IBM 71%
  • Procter & Gamble 45%
  • Coca-Cola 44%
  • Pfizer 60%
  • Twitter 67%
  • Bank of America 38%
  • Goldman Sachs Group 57%
  • General Electrics 58%
  • Amazon 33%
  • Oracle 33%
  • Tesla Motors 54%
  • PepsiCo 73%
Price
accuracy
51%
  • AFK Sistema 50%
  • AUD/USD 51%
  • EUR/RUB 80%
  • EUR/USD 44%
  • GBP/USD 54%
  • USD/CAD 49%
  • USD/CHF 38%
  • USD/JPY 45%
  • USD/RUB 0%
  • CAD/CHF 40%
  • EUR/AUD 48%
  • EUR/NZD 64%
  • EUR/GBP 54%
  • USD/DKK 48%
  • CAD/JPY 41%
  • USD/NOK 29%
  • EUR/CHF 43%
  • GBP/AUD 56%
  • GBP/NZD 74%
  • USD/SEK 46%
  • AUD/NZD 52%
  • GBP/CHF 49%
  • NZD/CHF 33%
  • AUD/CHF 42%
  • EUR/JPY 53%
  • CHF/JPY 48%
  • EUR/CAD 53%
  • GBP/JPY 59%
  • NZD/JPY 48%
  • AUD/JPY 47%
  • NZD/USD 46%
  • GBP/CAD 52%
  • NZD/CAD 47%
  • AUD/CAD 44%
  • Dash/Bitcoin 0%
  • BitcoinCash/USD 61%
  • Litecoin/USD 57%
  • Ethereum/USD 58%
  • Bitcoin/USD 63%
  • XRP/USD 55%
  • Silver 55%
  • Gold 55%
  • Alphabet 42%
  • Hewlett-Packard 0%
  • Adobe Systems 50%
  • Starbucks 67%
  • Nike 58%
  • Apple 27%
  • American Express 52%
  • JPMorgan Chase 26%
  • Microsoft 44%
  • McDonald's 38%
  • Netflix 27%
  • IBM 57%
  • Procter & Gamble 24%
  • Coca-Cola 31%
  • Pfizer 45%
  • Twitter 63%
  • Bank of America 34%
  • Goldman Sachs Group 35%
  • General Electrics 32%
  • Amazon 25%
  • Oracle 33%
  • Tesla Motors 49%
  • PepsiCo 49%
Profitableness,
pips/day
38
  • AFK Sistema -13
  • AUD/USD -2
  • EUR/RUB 12
  • EUR/USD -4
  • GBP/USD -4
  • USD/CAD -5
  • USD/CHF -2
  • USD/JPY 0
  • USD/RUB -20
  • CAD/CHF -1
  • EUR/AUD -6
  • EUR/NZD 1
  • EUR/GBP 2
  • USD/DKK 15
  • CAD/JPY -1
  • USD/NOK -104
  • EUR/CHF 0
  • GBP/AUD -1
  • GBP/NZD 11
  • USD/SEK -26
  • AUD/NZD 1
  • GBP/CHF -2
  • NZD/CHF -2
  • AUD/CHF 0
  • EUR/JPY 3
  • CHF/JPY -1
  • EUR/CAD -3
  • GBP/JPY 3
  • NZD/JPY -4
  • AUD/JPY -2
  • NZD/USD -1
  • GBP/CAD -8
  • NZD/CAD 0
  • AUD/CAD -2
  • Dash/Bitcoin -6
  • BitcoinCash/USD -27
  • Litecoin/USD 70
  • Ethereum/USD 39
  • Bitcoin/USD 23
  • XRP/USD 11
  • Silver -1
  • Gold -1
  • Alphabet 53
  • Hewlett-Packard -18
  • Adobe Systems -4
  • Starbucks -21
  • Nike 40
  • Apple -1
  • American Express 35
  • JPMorgan Chase -28
  • Microsoft 0
  • McDonald's 1
  • Netflix -6
  • IBM 30
  • Procter & Gamble -24
  • Coca-Cola 3
  • Pfizer 2
  • Twitter 43
  • Bank of America -3
  • Goldman Sachs Group -17
  • General Electrics 7
  • Amazon -3
  • Oracle -11
  • Tesla Motors -9
  • PepsiCo 29
More

Completed signals of Pfizer

Total signals – 39
Showing 21-39 of 39 items.
TraderDate and time createdForecast closure dateClosing quoteS/LCommentsTrend accuracy in %Price accuracy in %Profitability points
Peters19.01.202221.01.202254.5654.5600.0-96
Peters31.12.202104.01.202255.0055.0000.0-400
Millions11.12.202031.12.202159.050.0000.0-95
Peters21.12.202121.12.202159.0961.38100100.0184
Cox06.12.202113.12.202155.3054.40100100.030
Cox06.12.202113.12.202155.0054.20100100.030
TorForex16.09.202113.12.202155.000.00100100.0300
Cox06.12.202113.12.202154.7054.00100100.020
Peters23.11.202126.11.202153.5948.51100100.0254
TorForex16.09.202119.11.202152.000.00100100.0200
Cox08.11.202111.11.202150.000.00100100.050
Cox08.11.202111.11.202149.500.00100100.050
Cox08.11.202110.11.202149.000.00100100.050
Cox08.11.202108.11.202148.500.00100100.040
Cox18.10.202101.11.202143.660.0000.0-256
Cox18.10.202118.10.202141.100.00100100.030
Nina04.10.202113.10.202141.400.00100100.030
Nina04.10.202106.10.202141.700.00100100.030
Nina04.10.202106.10.202142.000.00100100.030

 

Not activated price forecasts Pfizer

Total signals – 25
Showing 21-25 of 25 items.
TraderSymbolOpen dateClose dateOpen price
PetersPfizer31.12.202114.01.202262.00
PetersPfizer31.12.202111.01.202261.00
PetersPfizer31.12.202106.01.202260.00
CoxPfizer06.12.202109.12.202154.30
CoxPfizer18.10.202115.11.202140.10

 

About promising companies in 2022
Pfizer, stock, About promising companies in 2022 PfizerPfizer holds one of the leading positions in the competition for the title of the No.1 enterprise in the world for the production of the best coronavirus vaccine. It was this fact that brought the company huge profits last year, and also provided financial support from the state. The vaccine produced by this company rightfully occupies the first place in the list of one of the best-selling.In the presented report for the 3rd quarter of the fiscal year, the drug sales forecast plans were increased by another 7.5%, which in monetary terms should be close to $36 billion. It is also considered important that for 2022 this indicator was revised taking into account the newly concluded agreements on the supply of booster vaccines to other states.According to the forecasts of analysts of the organization itself, the pandemic is unlikely to subside until 2024, in addition, another catalyst for the efficiency of the enterprise was the development of a drug from a new strain – Omicron. Tests on the latter are scheduled to begin in the coming days.The list of innovative developments of the company also includes a tablet drug for the treatment of covid, which has already shown 90% effectiveness. This fact was confirmed as a result of testing conducted on patients admitted to hospitals with a severe form of coronavirus disease. With the help of this experimental drug, the lethal outcome from this disease is almost completely excluded. Today, the company is waiting for the approval of the drug by the International Medical Association, after which it will be freely available.At the beginning of last year, the company's asset value was at $36.81, but by the end of the last reporting period it had already reached $58.95, with a projected maximum of $61.71. AstraZeneca and Johnson & Johnson are now included in the list of the pharmaceutical giant's main competitors.Since the beginning of the year, assets have grown by 60%, which is significantly more than the Industrial Average, the Dow Jones and the S&P 500. The company's management plans to continue playing ahead of the curve, if we take into account the situation with the actively spreading Omicron. Regardless of the rather restrained forecasts that analysts give for the future, Pfizer has a strong potential for growth.TeladocTeladoc is a virtual platform for medical consultations. In 2020, many watched in amazement as her assets literally soared. This is quite understandable by the situation with the coronavirus in the world, and the rapidly growing number of patients who need online consultations from professional doctors.In the last reporting year, the stock price fell by almost 50%. However, according to experts, in 2022 the cost may rise again, and reach as much as 126%, which corresponds to $215 per share.This leap is due to the acquisition of Livongo Health, specializing in patient support through AI, monitoring of patients with hypertension and diabetes mellitus. Taking into account these innovations, the company has received a great growth potential.The company's reports for the past year look no less encouraging. In the last quarter, revenue grew by 81%, the number of real users increased to 3.9 million people, an increase of 37%. A few more interesting figures – the estimate of annual income has increased from $2 billion to $2.01 billion.The number of patients wishing to use the company's services is growing relentlessly, which is confirmed by the fact that the number of chronic patients in a quantitative ratio of 24% participating in at least 1 company program. This figure is 8% higher than last year. Today, work is underway to expand the scope of the platform's services in the direction of providing assistance to patients with mental illnesses. To date, the potential of the site is able to provide a yield of $75 billion.It may very well be that the speed of development of Teladoc will be the highest among similar companies. According to official forecasts, the company's CAGR should increase by almost 30% between 2021 and 2024. This list includes:standard medical services;therapy of chronic diseases;mental problems.The company's management has already made its own forecasts for the future in terms of revenue and annual income. For example, the latter should reach $2.6 billion in the next reporting year, and by 2024, revenue will reach $4 billion.The volume of the total address market should reach $261 billion, and it may be higher if new users come with a stable regularity, and the company starts launching new, effective programs. That is, the growth prospects are very real and quite impressive.Experts advise to take a closer look at the company's assets, the price of which is currently held at a pre-pandemic level, and the financial indicators at that time were not so impressive. If skeptics claim that the growth of the company's financial indicators is due solely to the pandemic, they can be objected to, citing as an example the fact that even before the crisis, the growth rate was at the position of 74%.Upstart HoldingsIn the past financial year, Upstart Holdings has demonstrated quite impressive financial success:the income grew, and amounted to 280%, and this despite the fact that the shares were worth 60% less;by mid-autumn, assets totaled $401, instantly jumping as much as 800%;today their cost is $150.The company offers its clients an elite scoring system based on AI. Today, this scheme demonstrates excellent results, reducing the number of defaults by 75%, and the approval rate does not decrease.Before the transition to the market of loans and car loans, the company was engaged in unsecured loans. Some time later, the organization acquired the Prodigy platform, which was engaged in the sale of cars. As a result, a whole network of car dealerships was opened. For the 3rd quarter of last year, the organization reported an increase in the number of dealers by 219% compared to last year's figures.However, Upstart Holdings is not afraid of credit risks, since it is not engaged in loans, but is a lender. The company receives commissions from each loan issued by partners, and also develops its own software. It is assumed that the company's revenue by the end of the year will be in the range of 500 to 800 million dollars. Next year, this company plans to show a profit of up to 1 billion. This indicator will be historic for the company itself.Vertex PharmaceuticalsWorries about the collapse of the market force investors to look for reliable sources of income in the future. One of such enterprises can be safely called Vertex. The company's business has been bringing consistently high profits for many years, and the franchise provides very attractive conditions, and this is not counting the consistently high quality of products.There are those who rightfully consider the company an innovator and No.1 in the field of treatment for cystic fibrosis. Here the company can be considered a real monopolist and a leader in development potential. However, this is not enough for investors. Many people say that the company needs to develop, expand and introduce into other market areas. Several unsuccessful attempts, I must say, have already been made, but this is very little.Today, Vertex plans to create, together with CRISPR Therapeutics, a registration of therapy for editing CTX001 CRISPR genes. The latter include those that cope with pathologies such as sickle cell anemia and beta-thalassemia, in which only blood transfusion helps now.Equally important for the company is the promotion of VX-147, an element for the study of renal pathologies. A little earlier, the company's specialists said that phase 2 of the tests was very successful. The number of patients who suffer from this kind of diseases in America and Europe is more than 100 thousand. Almost an immense market for the company.Only active growth and expansion, as well as the franchise, will become the main driving force for the company in the near future. Vertex's collaboration with CRISPR Therapeutics in the aspect of gene editing looks very promising. In the 3rd quarter of last year, the company increased its investment in this technology. The launch of cooperation with Mammoth Biosciences and Arbor Biotechnologies has already been announced today.Today, the multiplier of the company's securities is at a fairly high level. Above the projected profit by 15.9 times. For an actively growing enterprise, this is not so much. That is why experts recommend taking a closer look at the company's ...
Read
US market: overview and forecast for December 15. Inflation is back in the spotlight
Dow Jones, index, NASDAQ 100, index, S&P 500, index, EURO STOXX 50, index, Hang Seng, index, Brent Crude Oil, energetic, Uber Technologies, stock, Pfizer, stock, ALCOA, stock, US market: overview and forecast for December 15. Inflation is back in the spotlight The market the day beforeTrading on December 14 on the main American stock exchanges ended in the red zone. The S&P 500 index dropped 0.75% to 4,634 points. The Dow Jones is down 0.30% and the Nasdaq is down 1.14%. Almost all industries closed in the red zone, and technology companies (-1.64%) and the real estate segment (-1.27%) became the leaders of the fall. The financial sector looked better than the market (+0.62%).Company newsCentene (CNC: +4.7%) has concluded a deal with an activist investor. Under its terms, the current CEO Michael Neidorf will retire in 2022.The CEO of Uber Technologies (UBER: +4.3%) said that the company's results for the fourth quarter will be at the upper limits of the predicted ranges.Alcoa Corp. shares (AA: +5.6%) were included in the S&P MidCap 400 index.ExpectationsStatistics regarding infections with the omicron strain COVID-19 do not inspire serious concerns today. According to the latest data, Pfizer-BioNTech and Johnson & Johnson vaccines are able to prevent a severe course of the disease. In this regard, investors' attention has shifted to the situation related to inflationary threats.The producer price index for November exceeded the consensus by 0.3 in a month-on-month ratio and increased by 0.8%. In annual comparison, the indicator increased by 9.6% with a forecast of 9.2%. Due to the increase in inflationary pressure, the Fed at the current meeting may consider the scenario of increased taping and a more intensive rate hike next year than originally planned.At the same time, the debt market is still weakly responding to the latest inflation data. The yield of two-year US government bonds increased by 2 basis points (bp), to 0.66%, and the yield of ten-year treasuries rose by only 1 bp, to 1.44%.We believe that the stock market will remain under pressure today due to the risks of activation of the Fed's actions aimed at curbing inflation.Most of the sites in Southeast Asia closed in the red. China's CSI 300 declined by 0.87%, Hong Kong's Hang Seng fell by 0.91% and only Japan's Nikkei 225 rose by 0.10%. EuroStoxx 50 has been adding 0.61% since the opening of trading.Brent crude futures are quoted at $73.7 per barrel. Gold is trading at $1770.4 per troy ounce.In our opinion, the S&P 500 will hold the upcoming session in the range of 4600-4650 points.MacrostatisticsRetail sales volume data for November will be published today (consensus: +0.9% mom after +1.7% a month earlier).Technical pictureThe S&P 500 changed its direction of movement, rushing to the lower border of the ascending channel and approaching the nearest support near the 50-day moving average. The RSI indicator, which has dropped to 50 points, indicates the probability of a sideways trend. The MACD gives mixed signals, canceling the upward reversal.In sightThe construction company Lennar Corporation (LEN) will present its quarterly report this Wednesday. The consensus forecast assumes an increase in its revenue by 24.6% YoY, to $8.506 billion, with an increase in EPS by 47.2% yoy, to $4.15. Lennar is the second largest developer in the United States after D.R. Horton, Inc. The report of the sector leader for the third quarter exceeded forecasts due to the continued high real estate prices and demand for it, which gives reason to expect corresponding results from ...
Avatar
Read
Market overview for the trading week of December 13-17, 2021
WTI Crude Oil, energetic, Natural Gas, energetic, Silver, mineral, Gold, mineral, Pfizer, stock, Market overview for the trading week of December 13-17, 2021 Events of the past weekOn Monday, news unexpectedly came from China that the People's Bank of China will reduce the rate of mandatory bank reserves for the second time this year, which will allow the country's banking system to release 1.2 trillion yuan. Investors did not immediately understand what caused such generosity of the Chinese regulator, as this is quite a serious step towards easing monetary policy. After that, everyone started talking that China would most likely soon take more aggressive measures to ease the financing conditions or, more simply, stimulate the economy with cash injections.And after that, something happened that everyone had been waiting for for so long, namely: Fitch lowered Evergrande's credit rating to "limited default" due to non-payment of two coupon payments after the grace period. The agency reported that Evergrande did not respond to the request for confirmation of the payment, and assumes that it was not made.And where is the chaos due to the default of Evergrande? And there was no chaos, and that's why. Firstly, the People's Bank of China lowered the required reserves rate in advance, flooding Chinese financial markets with liquidity, and secondly, investors were already prepared that this default would happen sooner or later. The Chinese government has done a lot of work with market participants, explaining to them that even without intervention from the authorities, there will be no crisis. Although the infusion of liquidity suggests that the authorities still intervened in the situation.In addition, Evergrande itself announced that it is negotiating with creditors on debt restructuring. And the chairman of Evergrande, Hui Ka Yang, was forced to sell the pledged shares of the company, and some forced sales, according to Bloomberg, began on Monday at the very moment when the company announced a large-scale restructuring. Apparently, as part of the restructuring program, these sales were carried out.Therefore, there is no panic! Despite all the horrors that have been escalated in the media, the situation is under control. Although this default may cause some distortions in the markets, its impact on a global scale is likely not to be significant.The omicron strain also remained in the spotlight last week. Scientists are puzzling over its severity and contagiousness. Scientists from South Africa warned that the effectiveness of Pfizer-BioNTech vaccines is decreasing with respect to omicron, but the report of these companies themselves states that although the effectiveness of two vaccinations is indeed reduced, but from the third (booster) vaccination it increases 25 times. However, Pfizer-BioNTech noted that they will continue their research, and they will have more data in about two weeks.Nevertheless, the Pfizer-BioNTech report did not deter many countries from introducing restrictive measures, as the EU continues to suffer from an increase in the incidence of COVID, and new cases of omicron infection continue to be detected around the world. By the way, some scientists say that this strain is not as severe in terms of the course of the disease as delta, and can become a kind of natural covid vaccine for those who have been ill.And, of course, on Friday, the long-awaited data on inflation in the United States were released. Since before the release of the data, President Biden urged not to pay attention to inflation for November, it seemed that something terrible would be waiting for us. As a result, we saw inflation within the forecasts, that is, at the level of 6.8%.Once again, the main component of inflation remained energy prices, or rather, gasoline. It is important to note the seasonal nature of the increase in gasoline prices, since Americans use motor vehicles more often during the holidays.In Biden's words, one can read confidence that the inflation data for December will be more moderate. However, in the US, the disruption of supply chains is still manifested quite strongly in the form of constant delays in the delivery of goods. Moreover, the number of idle vessels in ports and the waiting time for unloading is increasing, and this stimulates price growth in the run-up to the holidays.On the other hand, we can safely say that with inflation at 6.8% and unemployment at 4.2%, the US Federal Reserve will accelerate the curtailment of its asset repurchase program. According to various forecasts, the additional reduction will be from 15 to 30 billion per month. Thus, the overall rate of reduction is likely to grow to 75 billion per month.American MarketAmerican investors have been following the omicron virus all week, and as soon as Pfizer and BioNTech reported that their third dose of the vaccine was effective against the new strain, the markets were filled with cautious positivity.Meanwhile, the “week of silence” before the decision of the US Federal Reserve is coming to an end. The markets are worried, but they are not afraid of the reduction in asset repurchases themselves, but fears that the completion of this program will lead to an increase in interest rates.However, in my opinion, these concerns are exaggerated. The Fed understands that a sharp tightening of financing conditions can destroy all the progress made in the labor market. Realizing this, the Fed and the government will maintain soft financing conditions until the end, so as not to devalue the trillions of dollars poured into the economy earlier. And this is another reason not to be afraid of a reduction in asset repurchases, since it is unlikely to lead to a sharp increase in the interest rate.The S&P 500 index remained relatively stable after rising at the beginning of the week on positive news about the virus from Pfizer-BioNTech. Investors were expecting inflation data, and now they will be waiting for the US Federal Reserve meeting, which will be held on Wednesday.Now let's look at the commodity markets, and let's start with the classics - with metals.Commodity marketsMetalsGold declined slightly during the week – the market was expecting the publication of data on inflation in the US and data on a new strain of coronavirus. In general, gold is standing still, despite rising inflation and uncertainty with the virus. It turns out that investors are not looking for a safe haven or a safe haven, but a higher yield, because they are confident in the economy.Silver largely repeats the movements of gold, but looks much weaker. Since if we look at the graph of the ratio of the price of gold to the price of silver, we will see how silver has been getting cheaper against gold since November 25.And briefly about industrial metals. Copper continues to fluctuate on the general market uncertainty and adds 1% in a week. China continues to stimulate the economy, but omicron adds risks. I predict an increase in copper prices in the coming years against the background of an increase in the tax burden in key producing countries - Chile and Peru.GasGas prices in Europe are particularly volatile right now. Over the week, they have grown by 15% and are trading around $1200.Gazprom has again not reserved additional transit capacity for supplies through Ukraine. According to the company, a quarter of the gas pumped into the UGS of Europe this year has already been used.Although US lawmakers have removed the provision on the imposition of sanctions against Nord Stream 2 from the draft defense budget, the States do not give up the opportunity to influence the ban on the launch of the gas pipeline in the EU.Also, gas supplies from Norway to the EU countries decreased due to an unforeseen technical disruption in the operation of the gas pipeline. The European Union may need to restore its reserves after a difficult winter, which is reflected in summer gas futures.OilNow about oil. Black gold prices have increased by 5% in a week, and there are several reasons for this.More and more experts say that omicron does not cause serious symptoms, which Anthony Fauci also agrees with. However, this does not prevent countries from strengthening restrictions as the incidence increases, which negatively affects the oil markets.  Meanwhile, the Iranian ”nuclear deal" is getting cold again, and it seems that the US has decided to return to sanctions pressure on Iran so that they become more compliant in the negotiations.Saudi Aramco facilities were targeted by missiles and drones, which could reduce the supply of oil, and this also affected the price increase.Wood and lumberAnd now let's talk about a product that we haven't heard about for a long time. Lumber prices are rising again after the bubble blew out there in early summer. This week, the cost of lumber has increased by more than 10%, and since mid-November, the cost has almost doubled.In the USA, sawmills face a shortage of labor - workers are unwilling to work in such dangerous conditions at low wages. In Canada, recent floods have affected the transportation system, delaying or making it impossible to ship lumber to the United States.This causes concern in the market, because real estate prices may rise against this background. It is this type of expenditure that occupies a key place in the index of personal consumption expenditures.Events of the upcoming weekNext week will be really hot and difficult, as we are waiting for the monetary policy meetings of the US Federal Reserve, the European Central Bank, the Bank of England, the Bank of Japan and, finally, the Bank of Russia.Of course, most attention will be focused on the Fed, which, against the background of high inflation and low unemployment, will surely accelerate the reduction of asset repurchases. However, most likely, all this has already been taken into account by the market. The Federal Reserve meeting will be held on Wednesday.From other events. On Tuesday, we will find out the producer price index in the United States. A lot of data on China will be released on Wednesday, namely: the housing price index, retail sales, industrial production and the unemployment rate. Thus, we will be able to fully assess the state of the Chinese economy after the October crisis in the energy sector.A lot of UK data will also be released on Wednesday: inflation for November, the manufacturing price index, the retail price index and other reports. In addition, data on retail sales in the United States for November will be released on Wednesday.On Thursday, the publication of preliminary business activity indices for December for the eurozone and the United States will take place.Well, on Friday we are waiting for the decision of the Central Bank of the Russian Federation on the rate, which we have already talked ...
Avatar
Read
Pfizer remains the beneficiary of the vaccination campaign
Pfizer, stock, Pfizer remains the beneficiary of the vaccination campaign Pfizer (PFE) reported better than investors ' expectations for the second quarter. Its adjusted earnings per share were $1.07, exceeding forecasts by 10.3%. The company's revenue exceeded the consensus by 1.4% and amounted to $18.98 billion, increasing by 30% q/q and by 92.4% y/y. The company continues to demonstrate outstanding growth rates thanks to the supply of the COVID-19 vaccine. The main business of the pharmaceutical giant is developing at a more usual pace, having recovered after the pandemic.Sales of vaccines provided Pfizer with $9.2 billion in revenue, of which $7.8 billion came from the supply of the drug against COVID-19. The increase in the volume of sales of the Prevnar vaccine is mainly due to the effect of the low base of last year. In the segment of rare diseases (+31.4% y/y), sales of the drug Vyndaqel/Vyndamax increased most actively. This was due to the expansion of the use of this drug for the treatment of patients with transthyretin-amyloid cardiomyopathy in the United States, Japan and developed countries of Europe. The driver of revenue growth in the segment of drugs for internal diseases was the sales of Eliquis. The report notes an increase in sales on the international market of the anti-cancer blockbuster Ibrance, which is associated with the delayed diagnosis of cancer diseases during the pandemic. At the same time, in the United States, sales revenue decreased by 7% y/y due to an increase in the number of patients using the Patient Assistance program.Pfizer has introduced a number of pipeline updates. In the US, the FDA's decision on an additional application for Xeljanz was postponed due to doubts about the safety of the drug. For the same reason, the issuance of an opinion on the new drug Abrocitinib was postponed.Positive news for the company is associated with the expansion of the use of the COVID-19 vaccine. In particular, the effectiveness of the third dose of the vaccine against its "beta" and "delta" strains has been proven. At the moment, the company is conducting the third phase of trials of booster vaccinations, which involves 10 thousand patients. The COVID-19 vaccine, intended for children from 6 months to 11 years, is in the second-third phase of clinical trials.  Pfizer is preparing to provide the market with vaccination material for revaccination, which promises the company, as a leader in this segment, consistently high sales revenues.Pfizer's management raised its revenue forecast to $78-80 billion, which implies its growth by an average of 89% y/y. The EPS forecast has been increased from $3.55-3.65 to $3.95-4.05. Revenue from the sale of the coronavirus vaccine is expected to reach $33.5 billion against an earlier estimate of $26 billion. According to the company's calculations, the pre-tax profitability of the coronavirus vaccine should exceed 25%. Revenue excluding sales of the COVID-19 vaccine is expected in the range of $45-47 billion (an earlier forecast assumed a range of $44.6-46.6 billion), and EPS - in the range of $2.55-2.65, which is $0.05 higher than the previous estimate.Pfizer's reporting can be evaluated positively and set a target price for the company's shares at $44 with a "buy" recommendation ...
Avatar
Read
The main trends of pharmaceutical corporations in 2022
JPMorgan Chase, stock, Pfizer, stock, Moderna, stock, The main trends of pharmaceutical corporations in 2022 The JPMorgan Chase & Co (JPM) annual healthcare conference ended in San Francisco on January 13. This event with a forty-year history is considered one of the most significant in the medical community: pharmaceutical company executives participate in it, important statements about mergers and acquisitions are made on its site, new drugs are presented and breakthrough research is announced.Taking into account the new realities, for the second year in a row, the event is held in an online format. Let's list the most interesting industry trends that were outlined in the speakers' speeches.The use of RNA is recognized as the main trend in pharmacologyRibonucleic acid (RNA) is one of the three main macromolecules in the cells of all living organisms. Although the functions of RNA are not yet fully understood, studies show that this acid plays an important role in the coding and regulation of genes.Ribonucleic acid has attracted increased attention in connection with the development of vaccines against Covid-19. The previous generation of vaccines involved the introduction of a weakened virus into the body to form a subsequent immune response. Moderna (MRNA) and Pfizer (PFE) vaccines, created on the basis of informational RNA, work differently: they ”teach" human cells to produce a protein that triggers an immune response to prevent infection with coronavirus. Thus, the immune system of a vaccinated person is trained to recognize a protein containing Covid-19 and produce antibodies to it.As part of the conference, Pfizer announced the conclusion of three agreements with smaller industry players to accelerate RNA developments. The company sees a huge potential for RNA-based drugs - in particular, in the treatment of cancer and rare diseases. Amgen's interest in collaborating with Arrakis Therapeutics in the study of RNA is widely discussed, which could result in an order for several billion dollars for the latter. Pharmaceutical giants Johnson & Johnson (JNJ) and Eli Lilly (LLY) have so far limited themselves to restrained statements that they are exploring the possibilities of RNA technologies.Coronavirus pushes for partnerships instead of mergersFor the second year in a row, the healthcare sector has not heard about major deals. The coronavirus has shuffled all the cards. Previously, when a breakthrough technology was discovered, a pioneer was usually expected to be absorbed at a premium to the market, but the pandemic has taught companies to think in a new way, and now they are increasingly inclined to partnerships.The most telling example was the collaboration in the development of a coronavirus vaccine between Pfizer and BioNTech (BNTX). Through partnership, large players actually place an order for development to specialized companies with lower turnover. As a result, both sides benefit: pharmaceutical giants save money, and their partners receive orders and financing.Covid-19 ComebackHaving not had time to fully vaccinate against Covid-19, humanity faced a threat in the form of a new and more contagious variant of the coronavirus - "omicron". A strain from South Africa sets anti-records for morbidity in developed countries, involving pharmaceutical giants in a new development race.Some companies at the conference reported on the supply of their drugs against coronavirus. So, Moderna reported that its sales in 2021 amounted to $ 18.5 billion. GlaxoSmithKline (GSK), in partnership with Vir Biotechnology (VIR), reported on the supply to the US government of 600 thousand doses of the drug for the treatment of Covid-19 sotrivimab. Novavax (NVAX) announced that it has already made the first shipments to Europe of its Covid-19 vaccine, but did not specify the volume of orders. And Gilead Sciences (GILD) has informed that its drug remdesivir may soon be approved by the US regulator for the treatment of coronavirus.As for the development of drugs aimed directly against the omicron strain, only Regeneron (REGN) and Pfizer have made statements about this. Regeneron is going to test the treatment of omicron with antibodies in the first quarter, and Pfizer spoke about the progress in creating a new vaccine against Covid-19, which will also work against the new strain.There is an opinion that omicron as an opportunity rather than a threat. Perhaps omicron is our salvation from coronavirus restrictions, since the body of vaccinated people, having met with a new strain of virus from South Africa, gives an immune response, which can be considered as an alternative to booster vaccination. Which, in a global effect, can give massive protection against coronavirus infection.Patent diversificationLarge pharmaceutical companies are in a hurry to reassure investors who are beginning to pay attention to the patent terms of drugs that occupy a large share in their sales.As a rule, after the expiration of a patent for a particular drug, the market is flooded with its cheaper copies, which significantly reduces the revenue of the manufacturer of the original drug. Therefore, investors expect a diversified portfolio of developments from pharmaceutical giants, which will include not only expensive cancer drugs, but also a wide range of medicines for other diseases.For example, the patent of the anti-cancer drug from Merck & Co (MRK) Keytruda expires in 2028. Total sales of this drug for 2020 amounted to $14.4 billion, which accounted for 30% of Merck's revenue. If the company does not explain to investors before the expiration of the exclusivity period how it is going to compensate for the upcoming "loss” of sales volumes, the market reaction can be very negative.Analysts' opinionAn endless "arms race" continues in the pharmaceutical sector. Since breakthrough technologies and patents provide only a temporary competitive advantage, companies have to constantly set themselves new and new goals.However, the JPMorgan conference reflected some changes in the behavior of both pharmaceutical companies and their investors. Industry representatives confirmed their propensity to create partnerships, and investors confirmed their demands for diversification of development portfolios.The most obvious new trend among the elite of pharmacology has been the use of ribonucleic acid to encode the human immune system. It is assumed that with the proper development of technology, scientists will be able not only to achieve the necessary immune response to various infectious diseases, but also to eliminate defects in hormones or blood quality.And the main intrigue remains who will be the first to develop a vaccine against the omicron strain. Leading pharmaceutical giants are studying its characteristics, causes of origin and the reaction of previously vaccinated people to it. Thus, the beginning of this year is similar to the beginning of the previous one. Back then, we were also on the verge of creating a working version of the vaccine and watched the deadly virus walk around the planet ...
Read
About the trends of 2022
Litecoin/USD, cryptocurrency, Ethereum/USD, cryptocurrency, Bitcoin/USD, cryptocurrency, Pfizer, stock, Moderna, stock, About the trends of 2022 A couple of steps away from the new year, many are trying to predict the direction of market winds over the next year, and maybe several. We have also analyzed promising ideas of stock exchanges, and today we will share them with you. In general, everything promising in the coming year is connected with the healthcare sector. Next, let's talk about the two most promising companies in this segment.NovavaxNovavax company was one of the first to enter the championship in the development and creation of a vaccine, but in this case it is still far from the podium. Does the company have real prospects? Let's talk about this further.At the beginning of the year, many experts argued that it was simply not advisable to get involved in the company's struggle. This was due to the fact that there were already many manufacturers of similar drugs, and there was not enough space for new ones. As a result, the experts' "verdict" turned out to be reckless, and today many are confident that the company's assets are among the most attractive in the coming year.The vaccine was one of the first to be released in Europe. It is based on a protein, which in the future can become an alternative for patients who refuse to be vaccinated by Pfizer and Moderna, developed on the basis of RNA.In the spring of 2021, she presented the results of testing a new vaccine to the world, and in mid-summer, repeated tests were conducted in America. The effectiveness of the drug according to the test results ranges from 89.7% to 90.4%. This high indicator allowed the drug to get into the top three most effective, and the company to become a leader in the world market of manufacturers.Immediately after the publication of the results, it was expected that the company's assets should increase in value, but problems with bureaucratic hitches and permission to use the vaccine on world markets led to the fact that the share price remained in place, and subsequently even declined.Different sources explain this fall in different ways. Some argue that there are no special technological lines for the production of the drug in the United States. Others are sure that the drug simply does not meet the standards established in the state, contains unnecessary impurities that can cause a lot of side effects.Today, the drug is recognized in several countries of the world, including Indonesia, India. The vaccine has the permission of the WHO and the euroregulator, together with the submission of the application, it has received permission in several other countries.Today Novavax is awaiting regulatory approval in many countries around the world, including Australia, Canada, South Korea, and the United Kingdom. To accelerate the production of the drug, the company is sponsored by a number of large-scale organizations, including the Gates Foundation and even the American government.If new strains of coronavirus continue to appear, the disease will be transferred to the category of endemic. That is why vaccination will very soon become a routine procedure, and it is also likely that the demand for combined drugs will grow, which the company is currently testing.It is not enough to be able to treat well, you also need to correctly diagnose diseases. That is why next we will talk about the manufacturer of medical equipment for diagnostics.Thermo Fisher ScientificThermo Fisher Scientific is geographically located in Massachusetts. It is one of the leaders in the production of diagnostic tools and equipment used in laboratory and outpatient settings, as well as consumables. The production of coronavirus vaccines and medicines for this pathology is considered to be an equally significant area of activity of the enterprise. From the beginning of the pandemic to the present time, the demand for the company's products remains at a height, so the company today occupies a leading position in the field of medicine.In the spring of 2021, the International Health Association granted the company a license to produce SARS-CoV-2, a test for detecting covid-19. The volume of revenue received only from anti-weed products today has already amounted to $2.05 billion. With the emergence of new strains of coronavirus, the demand for the company's products will only grow.The TMO quarterly report, released on October 27, turned out to be quite strong. Revenue exceeded last year's figure by 15%, as well as by $ 1.2 billion in monetary terms. In total, it amounted to 37.1 billion dollars. According to forecasts, the amount of revenue will increase by $1 billion, and will amount to $7.7 billion.The forecast for this indicator was $40.5 billion, which shows the excellent position of the enterprise, especially for modern market realities. The growth of the company's asset price index exceeded the S&P 500, and reached 40%. With great probability, we can say that the group's positions will continue to be stable.Another trend of the century is electric carsThe vast majority of major analysts last year warned against acquiring Nio assets. At that moment, no one could have thought that the company's market capitalization could reach $90 billion. The volume of cars produced at the same time is 20 thousand units annually.However, over the past year, the company has managed to become an industry leader, and excellent financial results are expected in 2022. This is despite supply disruptions and other problems associated with the pandemic. The company has several new products that will help it increase its market share in China, and take a strong position on it.In the autumn of 2021, the number of cars produced by the company reached 10,900 units, which indicates an active growth in demand for cars with an engine capacity of more than 130,000 per year. The company is going to release about 600 thousand units of cars by the end of 2022. Nio's management plans to introduce three new electric cars to the world market. If the sales growth of cars remains at the planned indicators, then Nio may well have the opportunity to bypass Tesla by this parameter. At least in the Chinese market.An important advantage of the enterprise is the already launched Battery-as-a-service or BaaS program. It allows you to make a monthly payment, which allows you to change the battery on an electric car in the future or update the battery charge. It will also be possible to buy a car without a battery, rearranging it from old equipment.This system will allow the company to receive high-margin revenue in the long term. In addition, we should expect an increase in customer loyalty to the products. The company's assets showed a 13% growth in 2020, but during 2021 they managed to fall by 44%. Today they are stable at around $30. We are waiting for strong growth.Basic Attention TokenIt is already impossible to imagine the financial world without cryptocurrency. How to choose correctly between all the options – Bitcoin, Litecoin, Ethereum and others, and not be left out? An interesting option is offered by the Basic Attention Token.Over the past six months, investors' attention has been focused on tokens supporting the application. If we take into account that since the beginning of the year, the growth of bitcoin has approached 73%, then this is a minuscule compared to the start of the Siba-anu meme token, which soared to 47000000%. However, the main investment flow today is considered to be directed to a cryptocurrency that provides support for applications.In the large list of tokens, the Basic Attention Token from Brave Software deserves special attention. In particular, the token is especially attractive for investing for a long period. The company is now managed by B. Eich is the founder of Mozilla and JavaScript.Coins are mined using the Brave browser, where they are obtained by viewing advertising content. The web browser provides a high degree of security due to the built-in ad blocker and functions to block the collection of user data. Allows you to personally view ads released by program partners, as well as earn tokens by viewing it.Throughout December, bears dominated the cryptocurrency market, which negatively affected the VAT. As a result, the price of the token fell by 30% from the historical highs seen at the end of autumn. However, Bravo is confident that the price will recover its indicators very ...
Read
Message sent successfully.
We will contact you soon!